Saad Z. Usmani, MD

Articles

Dr Usmani on the Design of the CARTITUDE-4 Trial in Multiple Myeloma

April 24th 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the design of the phase 3 CARTITUDE-4 trial in multiple myeloma.

ASH 2021: Key Takeaways for Clinical Practice in Multiple Myeloma

February 4th 2022

Closing out his discussion on the ASH 2021 meeting, Saad Usmani, MD, shares key takeaways for clinical practice in multiple myeloma.

ASH 2021: Additional Highlights in Multiple Myeloma

February 4th 2022

Saad Usmani, MD, shares his excitement for additional clinical trial data in multiple myeloma presented at the ASH 2021 annual meeting.

Adding Venetoclax to Daratumumab and Dexamethasone in RRMM

February 4th 2022

In relapsed/refractory multiple myeloma, a recent study tested the addition of venetoclax to daratumumab and dexamethasone.

Relapsed/Refractory MM: Results From the BELLINI Study

February 4th 2022

Insight on the BELLINI study, which added venetoclax to bortezomib and dexamethasone for patients with relapsed/refractory multiple myeloma.

Daratumumab in NDMM: Subcutaneous vs IV Formulation

February 4th 2022

Closing out his discussion on newly diagnosed multiple myeloma, Saad Usmani, MD, considers the approval and use of subcutaneous daratumumab.

Triplet or Quadruplet Therapy in Transplant-Ineligible NDMM

February 4th 2022

In the context of transplant-ineligible newly diagnosed multiple myeloma, Saad Usmani, MD, considers the role of triplet versus quadruplet therapy.

Transplant-Eligible NDMM: Results From the MASTER Study

February 4th 2022

Expert perspective on results from the MASTER study analyzing daratumumab in combination with KRd in transplant-eligible newly diagnosed multiple myeloma.

Transplant-Eligible NDMM: Updated Results of the GRIFFIN Study

February 4th 2022

Updated results from the GRIFFIN study, which combined daratumumab with RVd in patients with transplant-eligible newly diagnosed multiple myeloma.

Dr. Usmani on Treatment Considerations for Second Relapse Myeloma and Beyond

April 20th 2021

Saad Z. Usmani, MD, FACP, discusses treatment considerations for patients with multiple myeloma who are in their second relapse or beyond.

Dr. Usmani on Future Research Directions for Nirogacestat/Teclistamab in Myeloma

March 23rd 2021

Saad Z. Usmani, MD, FACP, discusses future research directions with the combination of nirogacestat and teclistamab in patients with relapsed/refractory multiple myeloma.

Dr. Usmani on Key Findings From the SWOG 1211 Trial in High-Risk Multiple Myeloma

August 3rd 2020

Saad Z. Usmani, MD, FACP, discusses the key takeaways from the randomized phase 2 SWOG 1211 trial in patients with newly diagnosed, high-risk multiple myeloma.

Dr. Usmani on Current Challenges in High-Risk Multiple Myeloma

June 25th 2020

Saad Z. Usmani, MD, FACP, discusses current challenges in patients with high-risk multiple myeloma.

Dr. Usmani on Activity of Teclistamab in Relapsed/Refractory Multiple Myeloma

June 1st 2020

Saad Usmani, MD, discusses research with teclistamab (JNJ-64007957) in relapsed/refractory multiple myeloma presented at the 2020 ASCO Virtual Scientific Program.

Dr. Usmani Discusses Immunotherapy in Hematologic Malignancies

June 12th 2018

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses immunotherapy in hematologic malignancies.

Dr. Usmani on PD-1/PD-L1 Inhibitors in Hematologic Malignancies

April 30th 2018

Saad Z. Usmani, MD, clinical professor of medicine, UNC-Chapel Hill School of Medicine, chief, Plasma Cell Disorders Program, director, clinical research in hematologic malignancies, Levine Cancer Institute, discusses the evolution of PD-1/PD-L1 inhibitors in the treatment of patients with hematologic malignancies.

Dr. Usmani on Minimal Residual Disease in Multiple Myeloma

April 25th 2018

Saad Z. Usmani, MD, clinical professor of medicine, UNC-Chapel Hill School of Medicine, chief, Plasma Cell Disorders Program, director, clinical research in hematologic malignancies, Levine Cancer Institute, discusses the impact of minimal residual disease (MRD) on clinical practice.

Dr. Usmani Discusses Molecular Profiling in Myeloma

February 13th 2018

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses molecular profiling in patients with multiple myeloma.

Dr. Usmani on the Gimema-MMY-3006 Study for Multiple Myeloma

December 21st 2017

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses the phase III Gimema-MMY-3006 study for patients with multiple myeloma.

Dr. Usmani on Potential of Checkpoint Inhibitors in Multiple Myeloma

September 7th 2017

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses the potential of checkpoint inhibitors as monotherapy and in combination.